{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:30:23Z","timestamp":1792301423116,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nmd.2024.104468","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T16:04:24Z","timestamp":1728144264000},"page":"104468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9\u201311 February 2024, Hoofddorp, the Netherlands"],"prefix":"10.1016","volume":"44","author":[{"given":"Amelia","family":"Evoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Spagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-5173","authenticated-orcid":false,"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sithara","family":"Ramdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Natera-de Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cortes-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Behin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Tannemaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Damato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bonaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"EuMGA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Voerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.nmd.2024.104468_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.nmd.2024.104468_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2024.104468_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4-IgG service line testing in seronegative myasthenia gravis and controls","volume":"368","author":"Klein","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3988\/jcn.2023.19.1.60","article-title":"Development and application of a cell-based assay for LRP4 antibody associated with myasthenia gravis","volume":"19","author":"Chung","year":"2023","journal-title":"J Clin Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JND-230210","article-title":"Detection of autoantibodies against the acetylcholine receptor, evaluation of commercially available methodologies: fixed cell-based assay, radioimmunoprecipitation assay and enzyme-linked immunosorbent assay","volume":"11","author":"Diogenes","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.nmd.2024.104468_bib0009","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.nmd.2024.104468_bib0010","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.nmd.2024.104468_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120084","article-title":"Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis","volume":"432","author":"Mirian","year":"2022","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2024.104468_bib0012","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","volume":"38","author":"Li","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"10.1016\/j.nmd.2024.104468_bib0013","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.clinph.2019.04.005","article-title":"Guidelines for single fiber EMG","volume":"130","author":"Sanders","year":"2019","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0014","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0035-3787(06)75020-2","article-title":"[Misdiagnosis of mitochondrial myopathies: a study of 12 thymectomized patients]","volume":"162","author":"Ben Yaou","year":"2006","journal-title":"Rev Neurol (Paris)"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/112067210301300616","article-title":"Positive tensilon test and intracranial tumor: a case report","volume":"13","author":"Gupta","year":"2003","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1590\/0004-282x-anp-2020-0575","article-title":"Congenital myasthenic syndrome in a cohort of patients with 'double' seronegative myasthenia gravis","volume":"80","author":"Lorenzoni","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/mus.27521","article-title":"Autoantibody profile in myasthenia gravis patients with a refractory phase","volume":"65","author":"Veltsista","year":"2022","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mus.27774","article-title":"Incidence and causes of overdiagnosis of myasthenia gravis","volume":"67","author":"Andrapalliyal","year":"2023","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0019","doi-asserted-by":"crossref","first-page":"e16022","DOI":"10.1111\/ene.16022","article-title":"Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis","volume":"31","author":"Martinez-Harms","year":"2024","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.nmd.2023.01.002","article-title":"Autoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative Myasthenia gravis","volume":"33","author":"Hoffmann","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0021","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/mus.27822","article-title":"Clinical characteristics of anti-AChR-MuSK-LRP4 antibody-negative myasthenia gravis in China","volume":"67","author":"Li","year":"2023","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0022","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nmd.2023.01.006","article-title":"Chronic mimics of myasthenia gravis: a retrospective case series","volume":"33","author":"Harrison","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.nmd.2024.104468_bib0024","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0025","first-page":"7","article-title":"[The Japanese Clinical Guidelines 2022 for myasthenia gravis and lambert-eaton myasthenic syndrome: an overview]","volume":"76","author":"Murai","year":"2024","journal-title":"Brain Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British Neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2024.104468_bib0027","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0028","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0030","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/jcsm.13089","article-title":"Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis","volume":"13","author":"Keene","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0031","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nmd.2020.02.001","article-title":"242nd ENMC international workshop: diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019","volume":"30","author":"Munot","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.nmd.2024.104468_bib0032","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 7","key":"10.1016\/j.nmd.2024.104468_bib0033","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.nmd.2024.104468_bib0034","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0036","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mus.27103","article-title":"Autoantibodies in Japanese patients with ocular myasthenia gravis","volume":"63","author":"Nagaishi","year":"2021","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.nmd.2024.104468_bib0037","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1093\/brain\/awad153","article-title":"The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD)","volume":"146","author":"Allen","year":"2023","journal-title":"Brain"},{"issue":"14","key":"10.1016\/j.nmd.2024.104468_bib0038","first-page":"12","article-title":"Detection of antibodies against the acetylcholine receptor in patients with myasthenia gravis: a comparison of two enzyme immunoassays and a fixed cell-based assay","author":"Gambino","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.nmd.2024.104468_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2024.104468_bib0040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm-19-363","article-title":"Serological diagnosis of myasthenia gravis and its clinical significance","volume":"11","author":"Li","year":"2023","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0041","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mus.27500","article-title":"Positive acetylcholine receptor antibody in nonmyasthenic patients","volume":"65","author":"Sun","year":"2022","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.nmd.2024.104468_bib0042","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/ene.13081","article-title":"Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis","volume":"23","author":"Nikolic","year":"2016","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2024.104468_bib0043","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0044","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0168-5597(93)90130-H","article-title":"Repetitive nerve stimulation of anconeus in the assessment of neuromuscular transmission disorders","volume":"89","author":"Kennett","year":"1993","journal-title":"Electroencephalogr Clin Neurophysiol"},{"issue":"4","key":"10.1016\/j.nmd.2024.104468_bib0045","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/mus.25374","article-title":"New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis","volume":"55","author":"Bou","year":"2017","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0046","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/WNP.0000000000000398","article-title":"Diagnostic utility of repetitive nerve stimulation in a large cohort of patients with myasthenia gravis","volume":"34","author":"Amandusson","year":"2017","journal-title":"J Clin Neurophysiol"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0047","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.25214","article-title":"Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis","volume":"55","author":"Abraham","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0048","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1038\/s41598-023-30154-5","article-title":"The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis","volume":"13","author":"Tomschik","year":"2023","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.nmd.2024.104468_bib0049","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1016\/j.clinph.2016.09.012","article-title":"Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized myasthenia gravis","volume":"127","author":"Liik","year":"2016","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/mus.27573","article-title":"Single fiber electromyography and measuring jitter with concentric needle electrodes","volume":"66","author":"Sanders","year":"2022","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.nmd.2024.104468_bib0051","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.1139","article-title":"Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement","volume":"24","year":"2001","journal-title":"Muscle Nerve"},{"issue":"13","key":"10.1016\/j.nmd.2024.104468_bib0052","doi-asserted-by":"crossref","first-page":"e1800","DOI":"10.1212\/WNL.0000000000010619","article-title":"Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis","volume":"95","author":"Giannoccaro","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.nmd.2024.104468_bib0053","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.clinph.2019.03.033","article-title":"Repetitive ocular vestibular evoked myogenic potential stimulation for the diagnosis of myasthenia gravis: optimization of stimulation parameters","volume":"130","author":"Wirth","year":"2019","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0054","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/WNP.0000000000000956","article-title":"Test-retest reliability of repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis patients and healthy control subjects","volume":"41","author":"Keene","year":"2024","journal-title":"J Clin Neurophysiol"},{"issue":"10","key":"10.1016\/j.nmd.2024.104468_bib0055","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209395","article-title":"Accuracy of repetitive ocular vestibular-evoked myogenic potentials to diagnose myasthenia gravis in patients with ptosis or diplopia","volume":"102","author":"Valko","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0056","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jnnp-2022-329859","article-title":"Diagnosing myasthenia gravis using orthoptic measurements: assessing extraocular muscle fatiguability","volume":"94","author":"Keene","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0057","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement deposition at the neuromuscular junction in seronegative myasthenia gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nmd.2024.104468_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.834212","article-title":"The epidemiology and phenotypes of ocular manifestations in childhood and juvenile myasthenia gravis: a review","volume":"13","author":"Heckmann","year":"2022","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.nmd.2024.104468_bib0059","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00234-021-02753-4","article-title":"MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis","volume":"63","author":"Velonakis","year":"2021","journal-title":"Neuroradiology"},{"key":"10.1016\/j.nmd.2024.104468_bib0060","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/OPTH.S280508","article-title":"Radiological characteristics of extraocular muscles in myasthenia gravis patients with ocular manifestations: a case-control study","volume":"15","author":"Lueangaram","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0061","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nmd.2019.03.009","article-title":"A review of the histopathological findings in myasthenia gravis: clues to the pathogenesis of treatment-resistance in extraocular muscles","volume":"29","author":"Europa","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2024.104468_bib0062","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/mus.26172","article-title":"Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies","volume":"58","author":"Europa","year":"2018","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0063","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/ene.15173","article-title":"Congenital myasthenic syndrome: correlation between clinical features and molecular diagnosis","volume":"29","author":"Estephan","year":"2022","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.nmd.2024.104468_bib0064","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.nmd.2021.07.400","article-title":"Congenital myasthenic syndromes: where do we go from here?","volume":"31","author":"Ramdas","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.104468_bib0065","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.nmd.2024.104468_bib0066","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0067","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mus.25205","article-title":"Factors affecting outcome in myasthenia gravis","volume":"54","author":"Andersen","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.104468_bib0068","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0404.2006.00609.x","article-title":"Myasthenia gravis: disease severity and prognosis","volume":"183","author":"Romi","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"issue":"10","key":"10.1016\/j.nmd.2024.104468_bib0069","doi-asserted-by":"crossref","first-page":"e1426","DOI":"10.1212\/WNL.0000000000010209","article-title":"Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis","volume":"95","author":"Tomschik","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0070","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/mus.25154","article-title":"Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort","volume":"54","author":"Huda","year":"2016","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0071","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","article-title":"Antibody profile may predict outcome in ocular myasthenia gravis","volume":"118","author":"Galassi","year":"2018","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"10.1016\/j.nmd.2024.104468_bib0072","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jnnp.2006.102517","article-title":"Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands","volume":"78","author":"Niks","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2024.104468_bib0073","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2024.104468_bib0074","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/00207454.2018.1529669","article-title":"A tri-modal distribution of age-of-onset in female patients with myasthenia gravis is associated with the gender-related clinical differences","volume":"129","author":"Asmail","year":"2019","journal-title":"Int J Neurosci"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","article-title":"Gender differences in quality of life among patients with myasthenia gravis in China","volume":"18","author":"Dong","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.nmd.2024.104468_bib0076","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26104","article-title":"Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry","author":"Lee","year":"2018","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2024.104468_bib0077","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2024.104468_bib0078","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","article-title":"Fatigue in patients with myasthenia gravis. A systematic review of the literature","volume":"30","author":"Ruiter","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2024.104468_bib0079","doi-asserted-by":"crossref","first-page":"e00538","DOI":"10.1002\/brb3.538","article-title":"Fatigue in myasthenia gravis: risk factors and impact on quality of life","volume":"6","author":"Hoffmann","year":"2016","journal-title":"Brain Behav"},{"issue":"3","key":"10.1016\/j.nmd.2024.104468_bib0080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mus.25540","article-title":"Cognitive fatigue in patients with myasthenia gravis","volume":"56","author":"Jordan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0081","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/acn3.51492","article-title":"Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0082","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0083","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.24911","article-title":"Validation of the Besta Neurological Institute rating scale for myasthenia gravis","volume":"53","author":"Antozzi","year":"2016","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.nmd.2024.104468_bib0084","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1212\/WNL.0000000000201501","article-title":"Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis","volume":"100","author":"Bril","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.104468_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120480","article-title":"Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States","volume":"443","author":"Qi","year":"2022","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2024.104468_bib0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2024.01.025","article-title":"Assessing the comparative efficacy of plasmapheresis and Intravenous immunoglobulin in myasthenia gravis treatment: a systematic review and meta-analysis","volume":"121","author":"Ghimire","year":"2024","journal-title":"J Clin Neurosci"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0087","doi-asserted-by":"crossref","first-page":"e16229","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0088","doi-asserted-by":"crossref","first-page":"e16233","DOI":"10.1111\/ene.16233","article-title":"The epidemiology and societal costs of myasthenia gravis in Norway: a non-interventional study using national registry data","volume":"31","author":"Engebretsen","year":"2024","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2024.104468_bib0089","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0091","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2024.104468_bib0092","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.nmd.2024.104468_bib0093","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000536","article-title":"Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial","volume":"6","author":"Benatar","year":"2024","journal-title":"BMJ Neurol Open"},{"issue":"12","key":"10.1016\/j.nmd.2024.104468_bib0094","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0095","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0096","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2024.104468_bib0097","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2024.104468_bib0098","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pharmthera.2015.05.001","article-title":"Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds","volume":"152","author":"Sundahl","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.nmd.2024.104468_bib0099","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624009647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624009647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T12:09:22Z","timestamp":1731672562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624009647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":99,"alternative-id":["S0960896624009647"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.104468","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9\u201311 February 2024, Hoofddorp, the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.104468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"104468"}}